menu
    • menu
    [{"orgOrder":0,"company":"Famar","sponsor":"LaviPharm","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GREECE","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Paracetamol","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Famar","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Famar \/ LaviPharm","highestDevelopmentStatusID":"12","companyTruncated":"Famar \/ LaviPharm"},{"orgOrder":0,"company":"Elite Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Elite Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Elite Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Elite Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"LaviPharm","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Paracetamol","moa":"||COX1\/2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Lavipharm","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Lavipharm"}]

    Find Clinical Drug Pipeline Developments & Deals for Codeine Phosphate

    Menu

    Codeine Phosphate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Famar

                            Greece
                            Cancer Research
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothFAMAR CDMO- From early development to commercial manufacturing.

                            Lead Product(s) : Paracetamol,Caffeine,Codeine Phosphate

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : LaviPharm

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            FAMAR and Lavipharm Collaborate on Pharmaceutical Product Production

                            Details : Under the collaboration, FAMAR will produce two analgesic pharmaceutical products for Lavipharm: Lonarid N (paracetamol) and Lonalgal (caffeine anhydrous).

                            Product Name : Lonarid N

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 23, 2024

                            Lead Product(s) : Paracetamol,Caffeine,Codeine Phosphate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : LaviPharm

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            Famar

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Elite Pharmaceuticals

                            U.S.A arrow
                            Immuno-Oncology 360
                            Not Confirmed

                            Elite Pharmaceuticals

                            U.S.A arrow
                            Immuno-Oncology 360
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paracetamol,Codeine Phosphate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Elite Pharma Launches Acetaminophen and Codeine Tablets for Mild Pain Management

                            Details : Acetaminophen & codeine phosphate is a pain relief medicine. It is approved for use in adults for relief of mild to moderate pain & the management of moderate to severe pain.

                            Product Name : Tylenol-Generic

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 09, 2024

                            Lead Product(s) : Paracetamol,Codeine Phosphate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            Cancer Research
                            Not Confirmed

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            Cancer Research
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paracetamol,Caffeine,Codeine Phosphate

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : LaviPharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Asset Purchase Agreement for Lavipharm

                            Details : Company acquires two analgesic pharmaceutical products, Lonarid N® and Lonalgal®, used for fever and pain, for Greece and Cyprus markets with the intention to commercialize them internationally.

                            Product Name : Lonarid N

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 01, 2023

                            Lead Product(s) : Paracetamol,Caffeine,Codeine Phosphate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : LaviPharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth